Natera (NTRA) Chairman Matthew Rabinowitz Sells $20M of Stock
Executive Chairman Matthew Rabinowitz sold 50,000 shares of Natera, Inc. on October 15, 2026, for roughly $20.1 million.
Reviewed by automated data checks against the source filing. How we make and check alerts
Matthew Rabinowitz, EXECUTIVE CHAIRMAN at Natera, Inc. ($NTRA), sold 50,000 shares at an average price of $402.64, worth about $20.13 million, on October 15, 2026. The trade was reported to the SEC in a Form 4 filing and was made under a pre-arranged Rule 10b5-1 trading plan.
Since the trade, $NTRA is down 2.8% to date (from the $404.79 close on Oct 15, 2026).
NTRA
Natera, Inc.
Key Points
- Natera, Inc. Executive Chairman Matthew Rabinowitz sold 50,000 shares on October 15, 2026, worth about $20.1 million.
- The planned sale lowered his holdings by about 2.3%, leaving him with 2,119,394 shares.
- Wall Street firms including Citigroup, Barclays, and Morgan Stanley updated their price targets for the stock in October 2026.
Get $NTRA trade alerts by text
We text you when insiders, Congress or big funds trade $NTRA. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Natera, Inc. alert may contain errors. Disclosures
Matthew Rabinowitz, Executive Chairman of Natera, Inc. NTRA, sold 50,000 shares of the diagnostics company on October 15, 2026. According to a Form 4 filing with the Securities and Exchange Commission, the transaction took place at an average price of $402.64, resulting in a total value of about $20.1 million.
Inside Matthew Rabinowitz's Natera Trade
The sale was carried out under a pre-arranged trading plan. Following this transaction, Rabinowitz retains a sizable stake of 2,119,394 shares in the company, which cut his personal holdings by about 2.3%. Natera shares closed at $404.79 on the day of the trade.
Other Institutional Activity in Natera
Duquesne Family Office Llc grew its holdings by 122,845 shares, ending with 3,186,306 shares worth about $1.25 billion.
Natera, Inc. Stock Down 2.4%
The stock recently traded around $394.99, which is down about 2.4% from its close on the day of the insider trade.
Recent Earnings
Natera reported trailing twelve-month revenue of $2.71 billion alongside an earnings per share loss of $1.35. The company's next earnings report is scheduled for November 5, 2026.
Insider Buying and Selling at Natera, Inc.
Earlier in the year on June 26, 2026, multiple insiders made smaller purchases, including Rowan Chapman acquiring 1,674 shares, Lynch Thomas JR. buying 1,905 shares, Roelof Botha picking up 1,691 shares, and Eric Rubin taking 75 shares.
Analysts Set New Price Targets
Wall Street firms updated their views on the stock in October. On October 6, 2026, Citigroup maintained its Buy rating and raised its price target to $480 from $365. Later, on October 7, 2026, Barclays maintained an overweight rating with a target lifted to $475 from $340. Morgan Stanley maintained an overweight rating with a target of $435 on October 13, 2026. TD Cowen also maintained a Buy rating on October 13, 2026, moving its target to $480. Finally, on October 14, 2026, JP Morgan maintained an overweight rating with a $460 target. Overall, the stock carries a consensus strong buy recommendation and a mean price target of $403.89.
About Natera
Natera is an Austin-based healthcare company that develops molecular testing services. Its portfolio includes specialized blood tests for cancer recurrence monitoring, hereditary screening, and organ health assessment, serving patients and clinical partners globally.
Bottom Line
The executive's planned sale leaves him with a multi-million-share stake as the company heads toward its next financial results on November 5, 2026. Investors continue to monitor insider activity alongside institutional shifts and shifting analyst targets.
Related Filing Alerts
Source: Matthew Rabinowitz's Form 4 filing on $NTRA (Oct 15, 2026). Read the original filing: Form 4 filing on SEC EDGAR. Written by software, not financial advice. How we make alerts